Alex Sparreboom

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain
    Floris A de Jong
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:1105-10. 2006
  2. ncbi Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 3:757-66. 2003
  3. ncbi Limited potential of hepatic arterial infusion of irinotecan
    F A De Jong
    Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    J Chemother 16:48-50. 2004
  4. ncbi Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study
    Floris A de Jong
    Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Room AS 15, Groene Hilledijk 301, NL 3075 EA Rotterdam, The Netherlands
    Oncologist 11:944-54. 2006
  5. ncbi Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 6:1368-74. 2007
  6. ncbi Role of pharmacogenetics in irinotecan therapy
    Floris A de Jong
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Cancer Lett 234:90-106. 2006
  7. ncbi Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors
    Otto Soepenberg
    Daniel den Hoed Cancer Center, Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 11:1504-11. 2005
  8. ncbi Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1585-92. 2004
  9. doi A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 16:736-42. 2010
  10. ncbi ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition
    Floris A de Jong
    Department of Medical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 10:5889-94. 2004

Collaborators

Detail Information

Publications91

  1. ncbi Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain
    Floris A de Jong
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:1105-10. 2006
    ..Here we report on the disposition of irinotecan and its metabolites in plasma, urine, bile and feces of a single cancer patient with an external bile drain...
  2. ncbi Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 3:757-66. 2003
    ..Although complete responses have seldom been seen up until now, imatinib has proven to be extremely effective in the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors...
  3. ncbi Limited potential of hepatic arterial infusion of irinotecan
    F A De Jong
    Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    J Chemother 16:48-50. 2004
    ..In our view, future clinical implementation of irinotecan as HAI chemotherapy is unrealistic...
  4. ncbi Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study
    Floris A de Jong
    Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Room AS 15, Groene Hilledijk 301, NL 3075 EA Rotterdam, The Netherlands
    Oncologist 11:944-54. 2006
    ..Based on a pilot study, we hypothesized that concomitant administration of the antibiotic neomycin would diminish exposure of the gut to SN-38 and ameliorate the incidence and severity of diarrhea...
  5. ncbi Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 6:1368-74. 2007
    ..Here, we report on the pharmacokinetic and pharmacodynamic effects of this combination in a cancer patient...
  6. ncbi Role of pharmacogenetics in irinotecan therapy
    Floris A de Jong
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Cancer Lett 234:90-106. 2006
    ..Eventually, this may help to truly individualize the dosing of this (and other) anti-cancer agent(s), using a personal genetic profile of the most relevant enzymes for every patient...
  7. ncbi Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors
    Otto Soepenberg
    Daniel den Hoed Cancer Center, Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 11:1504-11. 2005
    ..To characterize the maximum-tolerated dose, recommended dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and food effect of orally administered irinotecan formulated as new semisolid matrix capsules...
  8. ncbi Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1585-92. 2004
    ..We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38...
  9. doi A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 16:736-42. 2010
    ..A randomized trial was done to assess the utility of an algorithm for individualized irinotecan dose calculation based on a priori CYP3A4 activity measurements by the midazolam clearance test...
  10. ncbi ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition
    Floris A de Jong
    Department of Medical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 10:5889-94. 2004
    ..The aim of this study was to evaluate the ethnic distribution and potential functional consequence of the ABCG2 421C>A genotype in cancer patients treated with irinotecan...
  11. ncbi Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:747-52. 2005
    ....
  12. ncbi Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 12:291-300. 2007
    ....
  13. ncbi Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:2719-26. 2007
    ..The purpose of this study was to determine the effects of cigarette smoking on the pharmacokinetics and adverse effects of irinotecan...
  14. ncbi Irinotecan pathway genotype analysis to predict pharmacokinetics
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:3246-53. 2003
    ..The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan...
  15. ncbi Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:4707-13. 2007
    ..Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese...
  16. ncbi Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 75:448-54. 2004
    ..We investigated the effects of the potent CYP3A4 inhibitor ketoconazole on the pharmacokinetics of docetaxel in patients with cancer...
  17. doi A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
    Karel Eechoute
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:5780-7. 2012
    ..As imatinib is mainly metabolized in the liver, our secondary aim was to elucidate the potential effects of the volume of liver metastases on exposure to imatinib...
  18. ncbi Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors
    Otto Soepenberg
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 11:703-11. 2005
    ..To assess the maximum-tolerated dose, toxicity, and pharmacokinetics of DE-310, a macromolecular prodrug of the topoisomerase I inhibitor exatecan (DX-8951f). in patients with advanced solid tumors...
  19. ncbi Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 74:364-71. 2003
    ....
  20. ncbi Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 14:227-32. 2003
    ..The data warrant a change from current practice in pharmacokinetic studies with this agent and provide further evidence that, in general, the choice of the appropriate assay matrix should be rationally based...
  21. ncbi Modulation of irinotecan metabolism by ketoconazole
    Diederik F S Kehrer
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, The Netherlands
    J Clin Oncol 20:3122-9. 2002
    ..To investigate the role of CYP3A4 in irinotecan pharmacology, we evaluated the consequences of simultaneous treatment of irinotecan with a potent enzyme inhibitor, ketoconazole, in a group of cancer patients...
  22. ncbi Effects of St. John's wort on irinotecan metabolism
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 94:1247-9. 2002
    ..These findings indicate that patients on irinotecan treatment should refrain from taking SJW because plasma levels of SN-38 were dramatically reduced, which may have a deleterious impact on treatment outcome...
  23. ncbi Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 795:383-8. 2003
    ..00 ng/ml for both compounds, with values for within-run precision (WRP) and between-run precision (BRP) of less than 10%. The method is currently being applied to investigate the blood distribution of CPT-11 and SN-38 in cancer patients...
  24. ncbi Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability
    Floris A de Jong
    Department of Medical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 10:4068-71. 2004
    ..Here, we prospectively evaluated the effects of administering a flat-fixed irinotecan dose to cancer patients, regardless of BSA...
  25. ncbi Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    Anticancer Drugs 13:767-75. 2002
    ..The strategies presented here provide the possibility to rapidly screen future candidate delivery vehicles with optimal characteristics for use as a solubilizer in clinical formulations of paclitaxel or other poorly water-soluble drugs...
  26. ncbi Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values
    Walter J Loos
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 24:1499-506. 2006
    ..We prospectively studied the usefulness of BSA-based dosing of cisplatin in patients at extremes of BSA values...
  27. ncbi Limited cerebrospinal fluid penetration of docetaxel
    Albert J ten Tije
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center Rotterdam, The Netherlands
    Anticancer Drugs 15:715-8. 2004
    ....
  28. ncbi Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel
    Carolien H Smorenburg
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 21:197-202. 2003
    ..Despite dose calculation using body-surface area (BSA), pharmacokinetics of most anticancer drugs show wide interindividual variability. In this study, we evaluated the role of BSA in paclitaxel disposition...
  29. ncbi Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan
    Walter J Loos
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 8:856-62. 2002
    ..Procedures to minimize formation of MEC, by the use of amber vials for NX 211 and by preparation of dilutions immediately before clinical use in a fashion completely protected from light, are now being routinely implemented...
  30. ncbi Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity
    Diederik F S Kehrer
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 20:1222-31. 2002
    ....
  31. ncbi Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan
    Ron H J Mathijssen
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, PO Box 5201, Rotterdam, 3008 AE, The Netherlands
    Curr Cancer Drug Targets 2:103-23. 2002
    ....
  32. pmc CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 19:3316-24. 2013
    ..Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity...
  33. doi Drug transporters and imatinib treatment: implications for clinical practice
    Karel Eechoute
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:406-15. 2011
    ..In addition, more pharmacogenetic studies will be needed to validate associations...
  34. ncbi Distribution of paclitaxel in plasma and cerebrospinal fluid
    Hans Gelderblom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 14:365-8. 2003
    ..Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration...
  35. ncbi Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors
    Otto Soepenberg
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:889-98. 2005
    ..To assess the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary antitumor activity of oral irinotecan given in combination with capecitabine to patients with advanced, refractory solid tumors...
  36. ncbi A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer
    Marco B Polee
    Department of Medical Oncology and Laboratory of Translational and Molecular Pharmacology, Rotterdam, The Netherlands
    Clin Cancer Res 10:1928-34. 2004
    ..To determine the maximum-tolerated dose, toxicity profile, and pharmacokinetics of a fixed dose of paclitaxel followed by increasing doses of carboplatin, given weekly to patients with advanced esophageal or gastric junction cancer...
  37. ncbi Effect of valspodar on the pharmacokinetics of unbound paclitaxel
    Albert J ten Tije
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Invest New Drugs 21:291-8. 2003
    ....
  38. ncbi Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant
    Johanna E A Portielje
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Cancer Immunol Immunother 54:37-43. 2005
    ..rHuIL-12, when administered at a dose of 0.1 microg/kg, showed minimal systemic effects. In conclusion, when IL-12 is used as an adjuvant, doses should not exceed 0.1 microg/kg, in order to avoid severe systemic inflammatory responses...
  39. ncbi Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices
    Otto Soepenberg
    Laboratory of Translational and Molecular Pharmacology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 799:15-22. 2004
    ..Validation results indicated that the methods are accurate and precise at lower limits of quantitation of 0.5-6.9 ng/ml. The methods were used to study the blood distribution and salivary concentrations in patients receiving DE-310...
  40. ncbi Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel
    Hans Gelderblom
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 8:1237-41. 2002
    ..This finding is consistent with the postulated concept that CrEL is largely responsible for the pharmacokinetic advantage for peritoneal cavity exposure to total paclitaxel compared with systemic delivery...
  41. doi Lifestyle habits as a contributor to anti-cancer treatment failure
    Floris A de Jong
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 44:374-82. 2008
    ..Also patient compliance to prescribed anti-cancer drugs is a factor frequently overlooked if treatment does not follow the expectations, which gains importance with the increasingly frequent prescription of oral anti-cancer agents...
  42. ncbi Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer
    Lia van Zuylen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Clin Cancer Res 10:1949-55. 2004
    ....
  43. ncbi Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Ron H J Mathijssen
    Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Oncologist 12:913-23. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  44. ncbi Pharmacological effects of formulation vehicles : implications for cancer chemotherapy
    Albert J ten Tije
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacokinet 42:665-85. 2003
    ..g. polyglutamates, analogues and prodrugs), or biological (e.g. oral drug administration) strategies. These continued investigations should eventually lead to more rational and selective chemotherapeutic treatment...
  45. ncbi Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer
    Albert J ten Tije
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam 3075 EA, The Netherlands
    Clin Cancer Res 9:2957-64. 2003
    ..v. infusion every 3 weeks. Blood samples for pharmacokinetic analysis were collected during the first and second course, and analyzed by liquid-chromatography with tandem-mass spectrometric detection...
  46. ncbi Medicinal cannabis in oncology practice: still a bridge too far?
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:2886-91. 2005
  47. pmc Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, 3075 EA Rotterdam, The Netherlands
    Oncologist 15:1063-72. 2010
    ..However, these reported associations are inconsistent, and data on patients with solid tumors are lacking. Here, we investigated the effects of MBL2 genotypes on irinotecan-induced febrile neutropenia in patients with solid tumors...
  48. pmc Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel
    Anne Joy M de Graan
    Department of Medical Oncology and Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:4433-40. 2012
    ..We hypothesized that (i) liver uptake of docetaxel is mediated by the polymorphic solute carriers OATP1B1 and OATP1B3 and (ii) inherited genetic defects in this process may impair systemic drug elimination...
  49. ncbi Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:151-9. 2003
    ..O. Bradley et al., Clin. Cancer Res., 7: 3229-3238, 2001). Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of DHA-paclitaxel...
  50. ncbi Population pharmacokinetics of cisplatin in adult cancer patients
    Felix E de Jongh
    Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 54:105-12. 2004
    ..To characterize the pharmacokinetics of the anticancer agent cisplatin, and explore the influence of patient covariates and interoccasion variability on drug disposition...
  51. ncbi Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples
    Peter de Bruijn
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anal Biochem 328:84-6. 2004
  52. ncbi Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
    Maja J A de Jonge
    Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 20:1923-31. 2002
    ..To assess the toxicity profile and dose-limiting toxicities (DLTs), to determine the maximum-tolerated dose, and to study the pharmacokinetics of ZD9331 when administered orally to patients with advanced solid tumors...
  53. ncbi Clinical studies of camptothecin and derivatives
    Otto Soepenberg
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Alkaloids Chem Biol 60:1-50. 2003
  54. ncbi Impact of body-size measures on irinotecan clearance: alternative dosing recommendations
    Ron H J Mathijssen
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, 3008 AE Rotterdam, The Netherlands
    J Clin Oncol 20:81-7. 2002
    ..To evaluate relationships between various body-size measures and irinotecan (CPT-11) clearance and metabolism in cancer patients, and to provide future dosing recommendations for this agent...
  55. ncbi Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry
    Alex Sparreboom
    Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Groene Hilledijk 301, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 773:183-90. 2002
    ..Our current method is approximately 60-100-fold more sensitive than previous assays, and will be used to define Tween 80 disposition in patients receiving Taxotere...
  56. ncbi Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions
    Hans Gelderblom
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 20:574-81. 2002
    ..Because CrEL clearance increases by extending the infusion duration from 3 to 24 hours, we hypothesized that exposure to unbound paclitaxel might also be schedule-dependent...
  57. ncbi Effect of ABCG2 genotype on the oral bioavailability of topotecan
    Alex Sparreboom
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:650-8. 2005
    ..0% versus 31.4%; p = 0.037). It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates...
  58. ncbi Altered irinotecan metabolism in a patient receiving phenytoin
    Ron H J Mathijssen
    Rotterdam Cancer Institute, Daniel den Hoed Kliniek, Department of Medical Oncology, 3075 EA Rotterdam, The Netherlands
    Anticancer Drugs 13:139-40. 2002
    ..This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38...
  59. pmc Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients
    Giuliano Ciarimboli
    Medizinische Klinik und Poliklinik D, Experimentelle Nephrologie, and Klinik und Poliklinik für Urologie, Universitatsklinikum Munster, Munster, Germany
    Clin Cancer Res 18:1101-8. 2012
    ..Knowledge of transporters responsible for the renal secretion of creatinine is key to a proper interpretation of serum creatinine and/or creatinine clearance as markers of renal function in cancer patients receiving chemotherapeutic agents...
  60. ncbi Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses
    Johanna E A Portielje
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:76-83. 2003
    ..Induction of IFN-gamma, considered a key mediator of antitumor effects of IL-12, is known to decline on repeated administrations. We studied whether other immunological effects of rHuIL-12 are tapered in the course of treatment...
  61. ncbi Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
    Erin R Gardner
    Clinical Pharmacology Research Core, SAIC Frederick, Frederick, USA
    Clin Pharmacol Ther 80:192-201. 2006
    ....
  62. ncbi Paclitaxel pharmacokinetics, threshold models, and dosing strategies
    Alex Sparreboom
    J Clin Oncol 21:2803-4; author reply 2805-6. 2003
  63. ncbi Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches
    Albert J ten Tije
    Clin Pharmacol Ther 74:509-10. 2003
  64. ncbi Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    George Cusatis
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1739-42. 2006
    ..99). The finding suggests that patients with reduced ABCG2 activity due to a common genetic variant are at increased risk for substrate drug-induced diarrhea, with implications for optimizing treatment with such agents...
  65. ncbi Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
    Sharyn D Baker
    Division of Experimental Therapeutics, The Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21237, USA
    J Natl Cancer Inst 94:1883-8. 2002
    ..We conclude that body surface area should not be used to determine starting doses of investigational agents in future phase I studies...
  66. ncbi Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea
    Rujia Xie
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 72:265-75. 2002
    ....
  67. ncbi Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib
    Nielka P van Erp
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 13:7394-400. 2007
    ..To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib...
  68. ncbi O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives
    Ryo Okamoto
    Department of Biochemistry and Biophysics, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami Ku, Hiroshima 734 8553, Japan
    Jpn J Cancer Res 93:93-102. 2002
    ....
  69. pmc Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients
    Zyting Chu
    Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
    Anticancer Drugs 19:275-81. 2008
    ..The corresponding median values for the apparent bioavailability of oral Genetaxyl were similar when compared with i.v. Genetaxyl, when calculated either on the basis of data for total paclitaxel (30.1%) or unbound paclitaxel (30.6%)...
  70. doi Inhibition of imatinib transport by uremic toxins during renal failure
    Ryan M Franke
    J Clin Oncol 26:4226-7; author reply 4227-8. 2008
  71. ncbi Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis
    Rujia Xie
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, SE 751 24 Uppsala, Sweden
    J Clin Oncol 20:3293-301. 2002
    ..To build population pharmacokinetic (PK) models for irinotecan (CPT-11) and its currently identified metabolites...
  72. pmc ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
    Tristan M Sissung
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4543-9. 2008
    ..Polymorphisms that are associated with ABCB1 expression and function may be linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients with androgen-independent prostate cancer receiving docetaxel...
  73. ncbi Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins
    Sylvia S W Ng
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, and Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Res 64:821-4. 2004
    ..It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy...
  74. ncbi Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 10:5038-47. 2004
    ..The purpose of this study was to determine the toxicities and characterize the pharmacokinetics of docetaxel and flavopiridol in patients with metastatic breast cancer...
  75. ncbi Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
    Luca Paoluzzi
    Clinical Pharmacology Research Core, National Cancer Institute, Building 10, Room 5A01, MSC 1910, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Pharmacol 44:854-60. 2004
    ..Screening for the UGT1A1(*)28 polymorphism may identify patients with altered SN-38 pharmacokinetics...
  76. pmc Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer
    Qingyu Zhou
    Laboratory of Clinical Pharmacology, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore 169610
    Br J Clin Pharmacol 59:415-24. 2005
    ....
  77. ncbi Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
    Alex Sparreboom
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Pharmacol Ther 76:38-44. 2004
    ..We performed an exploratory analysis to evaluate the effects of the natural allelic variant ABCG2 421C>A on the pharmacokinetics of diflomotecan...
  78. ncbi Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2
    Erin R Lepper
    National Cancer Institute, Clinical Pharmacology Research Core, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Pharmacogenomics 6:115-38. 2005
    ..This review focuses on recent advances in the pharmacogenetics of the ABC transporters ABCB1 and ABCG2, and discusses potential implications of genetic variants for the chemotherapeutic treatment of cancer...
  79. ncbi Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)
    Alex Sparreboom
    National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:4136-43. 2005
    ..To compare the preclinical and clinical pharmacokinetic properties of paclitaxel formulated as a Cremophor-free, albumin-bound nanoparticle (ABI-007) and formulated in Cremophor-ethanol (Taxol)...
  80. ncbi Relationship of systemic exposure to unbound docetaxel and neutropenia
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Pharmacol Ther 77:43-53. 2005
    ..Our objective was to evaluate the association between exposure to unbound docetaxel and neutropenia in patients with cancer and to identify factors influencing unbound docetaxel clearance...
  81. ncbi Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
    Erin R Lepper
    Science Applications International Corporation Frederick, Maryland, USA
    Clin Cancer Res 11:7398-404. 2005
    ..To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe...
  82. ncbi Pharmacogenetics of irinotecan metabolism and transport: an update
    Nicola F Smith
    Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Toxicol In Vitro 20:163-75. 2006
    ..This report provides an update on current strategies to individualize irinotecan chemotherapy based on each patient's genetic constitution, which may ultimately lead to more selective use of this agent...
  83. ncbi Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan
    Nielka P H van Erp
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The Netherlands
    Clin Cancer Res 11:7800-6. 2005
    ..Here, we investigated whether milk thistle affects the pharmacokinetics of irinotecan, a substrate for CYP3A4 and UGT1A1, in humans...
  84. ncbi Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
    Anja Henningsson
    Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 11:8097-104. 2005
    ..To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol)...
  85. ncbi Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen
    Stephan Mielke
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg i Br, Germany
    Anticancer Res 25:4423-7. 2005
    ..Paclitaxel pharmacokinetics were shown to be related to toxicity and survival. Patients and..
  86. ncbi Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients
    Alex Sparreboom
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    Invest New Drugs 22:285-9. 2004
    ..15). Overall, this study indicates that ABCB1 genotype might be correlated with tipifarnib pharmacokinetics, although considerable overlap in exposure measures between genotype groups was observed...
  87. ncbi Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry
    Erin R Gardner
    Clinical Pharmacology Research Core, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Rapid Commun Mass Spectrom 20:2170-4. 2006
    ..0. The assay is accurate and precise over the range of 2-2500 ng/mL and has been successfully applied to study the clinical pharmacokinetics of two formulations of paclitaxel, Genaxol and Genetaxyl, given orally and intravenously...
  88. ncbi Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
    ..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated...
  89. ncbi Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel
    Michael C Cox
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 12:4636-40. 2006
    ..This study examines the influence of garlic supplementation on the pharmacokinetics of docetaxel, a CYP3A4 substrate...
  90. pmc Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
    Tristan M Sissung
    Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    Eur J Cancer 42:2893-6. 2006
    ..This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics...
  91. ncbi Mechanism-based models for topotecan-induced neutropenia
    Frédéric Leger
    Institut Claudius Regaud, F 31052 Toulous, France
    Clin Pharmacol Ther 76:567-78. 2004
    ..A semiphysiologic pharmacokinetic-pharmacodynamic model was applied to describe topotecan-induced neutropenia, to quantify interindividual and intraindividual pharmacodynamic variability, and to study the effect of covariates on the model...